Wegovy produces an average weight loss of about 15% of body weight over 68 weeks, making it one of the most effective prescription weight loss medications available. For someone weighing 250 pounds, that translates to roughly 37 pounds lost. But the full picture of Wegovy’s effectiveness depends on your health profile, how long you stay on it, and what happens if you stop.
Weight Loss in Clinical Trials
The landmark STEP 1 trial tested Wegovy in nearly 2,000 adults with obesity but without type 2 diabetes. After 68 weeks (about 16 months), participants taking Wegovy lost an average of 14.9% of their body weight, compared to just 2.4% in the placebo group. Both groups also received lifestyle counseling, so that 14.9% reflects the drug’s contribution on top of diet and exercise guidance.
The two-year data from the STEP 5 trial confirmed these results hold up over time. At 104 weeks, average weight loss was 15.2% with Wegovy versus 2.6% with placebo. More than three-quarters of people on the drug (77.1%) lost at least 5% of their starting weight by the two-year mark, compared to about a third on placebo.
These are averages, which means some people lose significantly more and others less. Individual responses vary based on genetics, starting weight, diet, activity level, and adherence to the medication.
Smaller Results for People With Type 2 Diabetes
If you have type 2 diabetes, Wegovy still works, but the weight loss is more modest. In the STEP 2 trial, adults with type 2 diabetes lost an average of 9.6% of body weight over 68 weeks, compared to 3.4% with placebo. About 69% of participants on the drug lost at least 5% of their body weight.
The reduced effectiveness likely relates to the metabolic changes that come with diabetes, including insulin resistance and medications that can promote weight gain. A 9.6% loss is still clinically meaningful and enough to improve blood sugar control, blood pressure, and cholesterol levels.
How Wegovy Compares to Zepbound
The most common comparison is with Zepbound (tirzepatide), which works on two gut hormone pathways instead of one. In a head-to-head study, Zepbound at its higher doses produced about 20.2% body weight loss, while Wegovy at its standard doses produced about 13.7% over a similar timeframe of 72 weeks.
That gap has narrowed considerably. A newer high-dose formulation of Wegovy (7.2 mg, up from the standard 2.4 mg) showed roughly 21% weight loss over 72 weeks, putting it on par with Zepbound’s top doses. This higher-dose version gives people who plateau on the standard dose a path to greater results.
Benefits Beyond the Scale
Wegovy is the first weight loss drug FDA-approved to reduce the risk of serious cardiovascular events in adults with obesity or overweight. In the SELECT trial, which enrolled over 17,000 people with established heart disease, major cardiovascular events (heart attack, stroke, or cardiovascular death) occurred in 6.5% of those on Wegovy compared to 8% on placebo. That’s a meaningful reduction in real-world risk for a population already vulnerable to heart problems.
How It Works in Your Body
Wegovy is a synthetic version of GLP-1, a hormone your gut naturally releases after eating. It acts on appetite-regulating areas of the brain, reducing hunger, suppressing food cravings, and improving your sense of control over eating. In clinical testing, people on Wegovy ate significantly fewer calories when given unlimited access to food.
One common assumption is that the drug works partly by slowing digestion, keeping you feeling full longer. Research using indirect measurements of stomach emptying found no evidence of delayed gastric emptying with the 2.4 mg dose. The primary mechanism appears to be central, acting on the brain rather than the gut.
Side Effects to Expect
Gastrointestinal symptoms are the most common side effects and the main reason people discontinue treatment. Across clinical trials, 44% of people on Wegovy experienced nausea (versus 16% on placebo), 30% had diarrhea, 25% had vomiting, and 24% had constipation.
Most of these symptoms are mild to moderate and concentrated during the dose escalation phase. Wegovy uses a gradual five-step titration schedule to ease your body into the medication: you start at 0.25 mg weekly for the first four weeks, then increase every four weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg around week 17. If a particular dose is hard to tolerate, you can stay at that level for an extra four weeks before moving up.
What Happens When You Stop
This is one of the most important things to understand about Wegovy’s effectiveness. In an extension of the STEP 1 trial, researchers tracked participants for a year after they stopped the medication. Those who had been on Wegovy regained about two-thirds of the weight they had lost, averaging 11.6 percentage points of weight regain.
That pattern reflects the biology of obesity. The hormonal signals that drive hunger and fat storage don’t disappear because you’ve lost weight. When the medication is removed, those signals reassert themselves. For most people, Wegovy works best as an ongoing treatment rather than a short-term fix.
Cost and Access
Wegovy’s retail list price is $1,349 for a 28-day supply. With insurance coverage and the manufacturer’s savings card, some people pay nothing out of pocket. Without insurance, the savings card can bring the cost down to around $499 per month. Coverage varies widely: some insurers cover weight management medications, while others exclude them entirely. Checking your specific plan before starting treatment can save you from unexpected costs down the line.